Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | Director | June 25, 2026 | June 29, 2026 |
| Phio Pharmaceuticals Corp.PHIO · Entity 7889 | Director | February 13, 2019 | February 16, 2019 |
| SOLIGENIX, INC.SNGX · Entity 8067 | Director | September 27, 2018 | September 28, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celldex Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.09 · Expires 2036-06-25 | Direct | 26,000 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 26,000 · Balance 26,000 F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
Phio Pharmaceuticals Corp.
Report date February 13, 2019 · Filed February 16, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2019-02-13 transaction · row 1
1 source rowRow 1 · 2019-02-13 · Grant · Acquired 10,000 · Balance 20,000 F1: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.
SOLIGENIX, INC.
Report date September 27, 2018 · Filed September 28, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.67 · Expires 2028-09-26 | Direct | 17,964 |
Reported balance
After 2018-09-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-09-27 · Grant · Acquired 17,964 · Balance 17,964 F1: The stock option vests ratably on each of December 27, 2018, March 27, 2019, June 27, 2019 and September 27, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests ratably on each of December 27, 2018, March 27, 2019, June 27, 2019 and September 27, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 20:09 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001518575-26-000002 · form4-06292026_080611.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:07 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016216 · form4-06092025_080604.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:08 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017151 · form4-06172024_080643.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:11 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,300 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010038 · form4-06202023_080621.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,300 Underlying: Common Stock · 11,300 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:07 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,600 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006700 · form4-06172022_010653.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,600 Underlying: Common Stock · 13,600 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:20 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $28.00 | $0.00 |
DisclosureSEC source: 0001179110-21-006892 · edgar.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-06-17 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 12:04 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001179110-20-007589 · edgar.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2030-06-18 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 20:26 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001179110-19-007970 · edgar.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2029-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 02:06 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010825 · doc4.xml · nonDerivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 21:03 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | GrantStock Option (Right to Buy) · Derivative | 17,964 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001213900-18-013220 · ownership.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,964 Underlying: Common Stock · 17,964 shares Expires 2028-09-26 F1 · security: The stock option vests ratably on each of December 27, 2018, March 27, 2019, June 27, 2019 and September 27, 2019. F1 · derivative.exercise_date: The stock option vests ratably on each of December 27, 2018, March 27, 2019, June 27, 2019 and September 27, 2019. Read SEC document |
| August 01, 2018 Filed Aug 4, 2018 01:32 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-045458 · doc4.xml · nonDerivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:36 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008562 · edgar.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:32 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009169 · edgar.xml · derivative · entry 3 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2027-06-15 F2 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F4 · derivative.exercise_date: 100% of the total amount of shares subject to the Option vests on June 15, 2018. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:32 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009169 · edgar.xml · derivative · entry 2 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-15 F2 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F3 · derivative.exercise_date: Such option vests in three equal annual installments beginning June 15, 2018. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:32 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantCommon Stock, par value $0.001 per share | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-009169 · edgar.xml · nonDerivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: On June 15, 2017, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:21 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | GrantStock Option (Right to Buy) · Derivative | 13,100 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001213900-17-006383 · f4060817brownlie_soligenix.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,100 Underlying: Common Stock · 13,100 shares Expires 2027-06-07 F1 · security: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. F1 · derivative.exercise_date: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 22:21 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantStock option (right to buy) · Derivative | 2,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-17-007738 · doc4.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2027-02-01 F1 · derivative.exercise_date: The stock option vests in equal quarterly installments over one year beginning on the first quarterly anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.